ω-3 Polyunsaturated Fatty Acids on the Prognosis of Multiple Sclerosis: The Effect of Eicosapentaenoic acidSerafina Salvati* and Antonella Di Biase
Department Veterinary Public Health & Food Safety-IstitutoSuperiore di Sanità-Rome, Italy
- Corresponding Author:
- Serafina Salvati
Department Veterinary Public Health & Food Safety
IstitutoSuperiore di Sanità, Rome, Italy
E-mail: [email protected]
Received date: December 26, 2013; Accepted date: February 19, 2014; Published date: February 27, 2014
Citation: Salvati S, Di Biase A (2014) ω-3 Polyunsaturated Fatty Acids on the Prognosis of Multiple Sclerosis: The Effect of Eicosapentaenoic acid. J Neurol Neurophysiol S12:009. doi:10.4172/2155-9562.S12-009
Copyright: © 2014 Salvati S, et al. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The effect of nutrition and dietary supplements on the course of multiple sclerosis is a topic of great interest
to both patients and clinicians. The influence of ω-3 polyunsaturated fatty acids (PUFAs) on the development and
course of multiple sclerosis (MS) has been under investigation. A number of small, uncontrolled clinical trials with
fish oil (rich in eicosapentaenoic acid (EPA; 20:5 ω-3) and docosahexaenoic acid (DHA; 22:6 ω-3) have indicated
a possible beneficial effects of ω-3 PUFAs, but controlled trials have not been able to draw definitive conclusions.
Among ω-3 PUFAs, EPA has the most potent effect on myelinogenesis and inflammatory process, thus the conflicting
results could be due to the different mixtures of EPA and DHA contained in the various sources of fish oil. This review
discusses on the possible role of EPA in demyelinating diseases.